FDA OKs vitamin C trial for cancer

January 12, 2007

Federal approval of a clinical trial on intravenous vitamin C as a cancer treatment lends credence to alternative cancer care, U.S. researchers said.

Cancer Treatment Centers of America said it won Food and Drug Administration approval to begin the trial, a move the Illinois-based hospital group said adds credibility to its research into alternative methods for cancer medical care, the Chicago Tribune said Thursday. It is the first FDA-approved trial for CTCA.

Just a few patients will be eligible, said Christopher Lis, the firm's vice president of research and development.

"Only patients who have exhausted all other conventional treatment options are eligible to receive the therapy," Lis said.

The first phase will be to determine the optimal dose for the patients and to learn whether the treatment is safe and can be tolerated, Lis said. Additional studies over several years would be needed to demonstrate whether it is effective.

Earlier studies conducted with vitamin C supplements administered orally did not to demonstrate a clinical benefit to cancer patients.

Cancer Treatment Centers, with facilities in Illinois, Pennsylvania and Oklahoma, provides traditional and alternative treatment for cancer patients.

Copyright 2007 by United Press International

Explore further: Clinical trial hopes to provide less toxic treatment for prostate cancer

Related Stories

Clinical trial hopes to provide less toxic treatment for prostate cancer

October 18, 2017
Over the last decade, immunotherapy has emerged as one of the most promising and innovative fields in oncology. The goal of immunotherapy is to help a patient's own immune system fight cancer. A major breakthrough came in ...

CAR-T immunotherapy may help blood cancer patients who don't respond to standard treatments

October 20, 2017
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis is one of the first centers nationwide to offer a new immunotherapy that targets certain blood cancers. Newly approved ...

CAR-T immunotherapy now approved for certain adult lymphoma patients

October 20, 2017
The Food and Drug Administration (FDA) has approved a breakthrough cancer therapy known as CAR-T for use in adults with advanced lymphoma. The therapy uses a patient's own white blood cells, which are modified in a lab and re-trained ...

Therapeutic form of arsenic is a potential treatment for deadly type of brain cancer

October 17, 2017
From Sherlock Holmes to Agatha Christie, arsenic is often the poison of choice in popular whodunits. But in ultra-low dosage, and in the right form, this naturally occurring chemical element can be a potent force against ...

Study identifies breast cancer patients who would benefit from metastasis-specific treatment

October 20, 2017
Physicians currently have no tools to help them detect breast cancer patients who will suffer metastasis, a process that occurs in 15 to 20 percent of cases. In particular, they are unable to identify those patients that ...

Drug yields high response rates for lung cancer patients with harsh mutation

October 18, 2017
A targeted therapy resurrected by the Moon Shots Program at The University of Texas MD Anderson Cancer Center has produced unprecedented response rates among patients with metastatic non-small cell lung cancer that carries ...

Recommended for you

Major study of genetics of breast cancer provides clues to mechanisms behind the disease

October 23, 2017
Seventy-two new genetic variants that contribute to the risk of developing breast cancer have been identified by a major international collaboration involving hundreds of researchers worldwide.

Proton therapy lowers treatment side effects in pediatric head and neck cancer patients

October 23, 2017
Pediatric patients with head and neck cancer can be treated with proton beam therapy (PBT) instead of traditional photon radiation, and it will result in similar outcomes with less impact on quality of life. Researchers from ...

New study shows how cells can be led down non-cancer path

October 23, 2017
As cells with a propensity for cancer break down food for energy, they reach a fork in the road: They can either continue energy production as healthy cells, or shift to the energy production profile of cancer cells. In a ...

Microbiologists contribute to possible new anti-TB treatment path

October 23, 2017
As part of the long effort to improve treatment of tuberculosis (TB), microbiologists led by Yasu Morita at the University of Massachusetts Amherst report that they have for the first time characterized a protein involved ...

Big Data shows how cancer interacts with its surroundings

October 23, 2017
By combining data from sources that at first seemed to be incompatible, UC San Francisco researchers have identified a molecular signature in tissue adjacent to tumors in eight of the most common cancers that suggests they ...

Symptom burden may increase hospital length of stay, readmission risk in advanced cancer

October 23, 2017
Hospitalized patients with advanced cancer who report more intense and numerous physical and psychological symptoms appear to be at risk for longer hospital stays and unplanned hospital readmissions. The report from a Massachusetts ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.